The increase in bone mineral density by bisphosphonate with active vitamin D analog is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis

References

• Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374:254–62.
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761–71.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for bone and mineral research. J Bone Miner Res. 2014;29:1–23.
   PubMed Web of Science ®Google Scholar
• Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3–23.
   PubMed Web of Science ®Google Scholar
• Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, et al. Osteonecrosis of the Jaw in the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS). J Bone Miner Res. 2016;31:336–40.
   PubMed Web of Science ®Google Scholar
• Saita Y, Ishijima M, Mogami A, Kubota M, Baba T, Kaketa T, et al. The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab. 2015;33:311–8.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM. Goal-directed treatment of osteoporosis. J Bone Miner Res. 2013;28:433–8.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab. 2013;98:946–53.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on goal-directed treatment for osteoporosis. J Bone Miner Res. 2017;32:3–10.
   PubMed Web of Science ®Google Scholar
• Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014;174:1126–34.
   PubMed Web of Science ®Google Scholar
• Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99:4546–54.
   PubMed Web of Science ®Google Scholar
• Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31:16–35.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Majumdar SR, Morin SN, Lix LM. Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: a registry-based cohort study. Ann Intern Med. 2016;165:465–72.
   PubMed Web of Science ®Google Scholar
• Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006;260:245–54.
   PubMed Web of Science ®Google Scholar
• Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M, et al. Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. J Bone Miner Metab. 2017;35(1):1–5.
   PubMed Web of Science ®Google Scholar
• Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477–501.
   PubMed Web of Science ®Google Scholar
• Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25:585–91.
   PubMed Web of Science ®Google Scholar
• Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009;85:398–404.
   PubMed Web of Science ®Google Scholar
• Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02. Curr Med Res Opin. 2011;27:1273–84.
   PubMed Web of Science ®Google Scholar
• Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, et al. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int. 2015;26:1193–202.
   PubMed Web of Science ®Google Scholar
• Ishii M, Ito M, Mizutani M. Actual practice of nutritional education for patients with osteoporosis. Clin Calcium. 2005;15:1523–8.
   PubMedGoogle Scholar
• Uenishi K, Ishida H, Nakamura K. Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis. J Nutr Sci Vitaminol. 2008;54:25–9.
   PubMed Web of Science ®Google Scholar
• Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643–6.
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007;50:927–37.
   PubMed Web of Science ®Google Scholar
• Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001;19:331–7.
   PubMed Web of Science ®Google Scholar
• Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, et al. Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab. 2013;31:247–57.
   PubMed Web of Science ®Google Scholar
• McNamara EA, Kilim HP, Malabanan AO, Whittaker LG, Rosen HN. Enhanced precision of the new Hologic Horizon model compared with the old Discovery model is less evident when fewer vertebrae are included in the analysis. J Clin Densitom. 2018;21:125–9.
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;AC-19:716–23.
   Web of Science ®Google Scholar
• Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294:2336–41.
   PubMed Web of Science ®Google Scholar
• Joo NS, Dawson-Hughes B, Kim YS, Oh K, Yeum KJ. Impact of calcium and vitamin D insufficiencies on serum parathyroid hormone and bone mineral density: analysis of the fourth and fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-3, 2009 and KNHANES V-1, 2010). J Bone Miner Res. 2013;28:764–70.
   PubMed Web of Science ®Google Scholar
• Samozai MN, Kulkarni AK. Do calcium supplements increase serum and urine calcium levels in post-menopausal women? J Nutr Health Aging. 2015;19:537–41.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures–a randomized, active comparator, double-blind study. Bone. 2011;49:605–12.
   PubMed Web of Science ®Google Scholar
• Hagino H, Takano T, Fukunaga M, Shiraki M, Nakamura T, Matsumoto T. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J Bone Miner Metab. 2013;31:183–9.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Takano T, Fukunaga M, Shiraki M, Matsumoto T. Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. J Bone Miner Metab. 2013;31:417–22.
   PubMed Web of Science ®Google Scholar
• Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009;44:1078–84.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int. 2009;20:1429–37.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000;283:1318–21.
   PubMed Web of Science ®Google Scholar
• Sebba AI. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther. 2008;30:443–52.
   PubMed Web of Science ®Google Scholar
• Favus MJ, Goltzman D. Regulation of Calcium and Magnesium. In: Rosen CJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8th ed. Hoboken (NJ): John Wiley & Sons; 2013. p. 172–9.
   Google Scholar
• Bullamore JR, Wilkinson R, Gallagher JC, Nordin BE, Marshall DH. Effect of age on calcium absorption. Lancet. 1970;2:535–7.
   PubMed Web of Science ®Google Scholar
• Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, et al. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Vol. 20. Wayne (PA): Clinical and Laboratory Standards Institute; 2010. p. 72.
   Google Scholar